BERLIN (dpa-AFX) – The radiation and medical technology group Eckert & Ziegler (EckertZiegler Strahl- und Medizintechnik) has secured a major order from the USA. This involves the delivery of carrier-free lutetium-177 to the US company Point Biopharma, the SDAX-listed company announced on Tuesday night. The agreement has a term of ten years with a total sales volume of more than 100 million euros. The contract is still subject to the condition that the material produced by the Germans proves to be suitable for the preparation envisaged by the client. The expected sales volume is based on the assumption of market approval.
Eckert & Ziegler plans to invest around ten million euros in its own location in Wilmington in the US state of Massachusetts to expand its manufacturing capacities. The agreement is expected to generate initial sales from 2023 and, provided that Point’s products receive market approval, generate substantial income./he
Selected lever products on Eckert Ziegler Radiation and Medical Technology
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Eckert Ziegler Radiation and Medical Technology
The leverage must be between 2 and 20